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What should the optimal target hemoglobin be? Partial correc- worsens as renal function declines, such that when creati-
tion of anemia in patients with chronic kidney disease (CKD) nine clearance is below 25 mL/min, the prevalence of
improves anemia-related symptoms. However, controversy re- anemia is approximately 87% [1]. These findings suggestmains as to whether total correction of anemia provides bene-
that patients with CKD may be anemic for a long timefits over and above those afforded by partial correction. There
is some evidence showing that normalization of hemoglobin during the progression of the disease. If this is the case,
(Hb) concentrations may improve the cardiac hyperdynamic then patients are exposed to an important risk factor
state in CKD patients and reduce the diameter of the left that could influence clinical outcomes.
ventricle. Further studies have shown that normalization of
As oxygen supply to the tissues decreases due to ane-Hb improves cognitive function and physical capacities as mea-
mia, several compensatory mechanisms develop, includ-sured by quality of life (QoL) tests. Large studies have shown
that in dialysis patients there is a close inverse relationship ing cardiovascular adaptations [2]. Owing to these sys-
between hematocrit (Hct) levels and mortality and morbidity. tems of adaptation, anemia is largely responsible for the
Moreover, there is evidence suggesting that Hct levels higher
significant detrimental cardiac effects occurring in CKDthan those recommended by European Best Practice Guide-
patients (Table 1).lines (EBPG) and the National Kidney Foundation Dialysis
Outcome and Quality Initiative (NKF-DOQI) provide better Treatment of CKD patients with epoetin leads to an
outcomes for patients with CKD. However, when Hb concen- increase in hemoglobin (Hb) concentrations, which im-
trations are increased to normal in selected patients with car- proves anemia-related symptoms. At present there is nodiac disease, congestive heart failure, or ischemic cardiopathy,
clear evidence as to what the target Hb concentrationhigher mortality rates are evident. Therefore, while the major-
for these patients should be. The EBPG [3] and theity of patients with CKD may experience significant benefits
when Hb is normalized, it seems prudent to recommend indi- NKF-DOQI Guidelines for the treatment of anemia
vidualized target Hb concentrations for each patient, taking of CKD [4] establish a minimum Hb concentration of
into account factors such as age, sex, employment status, physi-
11 g/dL. Importantly, the EBPG features an open-endedcal activity, and co-morbidities.
target Hb that includes the provision to normalize Hb.
However, some recent studies have reached controver-
sial conclusions on the benefits of normalizing Hb con-Anemia is a very frequent complication in patients with
centrations. On the one hand, some authors have wit-chronic kidney disease (CKD). It affects over 90% of
nessed an increase in the beneficial effects of anemiapatients undergoing renal replacement therapy with dial-
therapy when Hb is normalized [5–8] while other authorsysis, but it may begin in the early stages of renal insuffi-
have experienced conflicting results in selected groupsciency, well before the initiation of dialysis. The preva-
of patients [9]. The aim of this review is to summarizelence of anemia in CKD correlates inversely with
the advantages and disadvantages of normalizing Hbresidual renal function. In the Canadian multi-center
levels in CKD patients.study of renal anemia, the prevalence of anemia was
found to be approximately 25% when creatinine clear-
ance is higher than 50 mL/min. Anemia progressively
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Table 1. Detrimental effects of anemia in patients there have been few studies specifically investigating this
with chronic kidney disease
phase of CKD. Portole´s et al have shown that in 11
Decreased Increased patients with CKD, the improvement in Hct is accompa-
Exercise capacity Depression nied by a significant reduction of cardiac index and of
Skeletal muscle oxidative capacity Sleep/awake pattern left ventricular mass, despite not achieving normal Hb
Coagulation Cardiac output
concentrations [17]. Hayashi et al showed that in 9 pre-Immune response Angina
Cognitive function Left ventricular hypertrophy dialysis patients the normalization of Hb resulted in a
Sexual function Cardiac failure complete regression of LVH without negative influence
Appetite/nutrition Myopathy
on the blood pressure or on the rate of progression ofQuality of life Morbidity
Growth in children Mortality renal failure. [18]. A multi-center Spanish study of 102
pre-dialysis patients showed that partial correction of
anemia (Hb from 9 to 11 g/dL) resulted in a decrease
in left ventricular mass index at 6 months. The most
promising effect was in patients without basal LVH whoof the left ventricle (eccentric LVH), where the diameter/
wall thickness ratio remains constant. remained normal when treated with epoetin, while non-
treated patients experienced increased left ventricularFrom the very first clinical experiences with epoetin,
various studies have shown that partial correction of ane- mass (abstract; Valderra´bano et al, Nephrol Dial Trans-
plant 15:A114, 2000. These data suggest, once again, thatmia is accompanied by the partial regression of LVH
[10–13]. However, these studies were conducted on rela- early anemia correction protects against the development
of LVH.tively small groups of patients, and did not aim to fully
normalize Hb concentrations. A Spanish multi-center An observational study of 4866 pre-dialysis patients
was recently published by Fink et al, showing that thestudy of 91 hemodialysis patients has also shown that
the increase in Hb concentrations with epoetin reduces mortality risk after initiating dialysis was lower for pa-
tients treated with epoetin before dialysis compared withthe severity of LVH. This improvement is due to a sig-
nificant decrease in left ventricular diameter, but the patients who were not treated. However, there was no
relationship between pre-dialysis Hct and mortality rate,overall thickness of the left ventricular walls does not
change (abstract; Lo´pez Go´mez et al, J Am Soc Nephrol suggesting that epoetin therapy prior to dialysis confers
an increased probability of survival when the patients11:A1488, 2000.
It is unclear whether Hb normalization may have an reach end-stage renal disease (ESRD) [20]. Thus, it seems
that correction of anemia must be initiated early in theadded advantage to such patients. The Canadian multi-
center study has shown that complete correction of ane- progression of CKD, and that complete correction may
add complementary beneficial effects. However, new tri-mia fails to induce regression of well established concen-
tric LVH or left ventricular dilation, but it appears to als are necessary to confirm this hypothesis. Accordingly,
several studies currently underway in Australia, Canada,prevent left ventricular dilation in patients with normal
left ventricular volume [15]. However, in a prospective, and the UK, which, along with the Cardiovascular Risk
reduction by Early Anemia Treatment with Epoetin betarandomized, and doubled-blind cross-over study of 14
hemodialysis patients, Hb normalization was followed (CREATE) trial [21], are attempting to assess the effect
of earlier anemia treatment on cardiac function. Theby a reduction in left ventricle end diastolic diameter
with a 5% reduction in left ventricular mass index that results are promising and could show clear evidence of
the preventive effect of early anemia correction in LVHwas not statistically significant [8].
The US Normal Hemocrit Trial showed that complete and cardiovascular morbidity. They could also answer
the question of whether or not achieving normal targetcorrection of anemia in hemodialysis patients with symp-
tomatic heart failure or ischemic heart disease was associ- Hb concentrations has beneficial effects on long-term
outcomes for CKD patients.ated with a trend towards higher mortality rates com-
pared with similar patients in the low target Hct group
Cognitive function[9]. These studies suggest that when there are important
alterations in cardiac structures, the beneficial effect of Various studies using different neuropsychological
and neurophysiological tests in dialysis patients havethe total correction of anemia is very limited, although
the results of the Canadian study have shown a favorable demonstrated that raising Hb/Hct to the levels recom-
mended by the EBPG (Hb11 g/dL in85% of patientseffect on the prevention of LVH once the developing
anemia is corrected. with uncomplicated anemia) [3] and the NKF-DOQI
Guidelines (Hct between 33% and 36%) [4] is accompa-LVH may be evident very early in the progression of
CKD [16]. The US and Canadian data combined suggest nied by an improvement in cognitive function [22–24] and
in electroencephalogram (EEG) characteristics [22, 25].that the prevention of structural heart changes should
be initiated early, i.e., in the pre-dialysis phase. However, Metry et al suggest that maximal level of oxygen deliv-
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ery to the brain occurs when Hct levels are higher than are believed to be the most apparent. A comparison of
very anemic patients with those treated to levels recom-36% [26]. This hypothesis brings once more to the fore
the question: does normalizing Hb concentrations have mended by the EBPG [3] and NKF-DOQI [4] (Hb
11–12 g/dL) shows that the QoL scores are strongly re-benefits additional to achieving existing agreed targets?
To this end, Pickett et al studied the effects of raising lated to Hb concentrations [38]. However, an aspect that
is not so well studied is the evaluation of QoL when HbHct from 31.6% to 42.8% in a group of 20 hemodialysis
patients. EEGs revealed significant improvement, and im- concentrations reach normal values. The US Normal He-
matocrit Trial showed that physical function, assessedprovement was also shown in electrophysiological tests
mainly affecting P300 latency and amplitude [7]. by SF-36 questionnaire increased 0.6 points for each
percentage point increase in Hct [9]. In the CanadianA study of the effects of epoetin therapy on sleep,
sleep disorders, and daytime sleepiness on hemodialysis multi-center study, fatigue, depression, and relationship
capacities improved significantly when normal Hb con-patients (the SLEEPO trial), conducted by Benz et al
showed that after increasing mean Hct from 32.3% to centrations were achieved [15]. The Spanish Co-opera-
tive Renal Patients QoL Study Group examined the ef-42.3%, some parameters of quality of sleep such as peri-
odic leg movement, arousing periodic limb movements fect on the QoL and functional status in 156 hemodialysis
patients after achieving an Hct close to normal. After in-in sleep (PLMS), or maintenance wakefulness assessed
by polysomnography were significantly improved (ab- creasing the epoetin dose by approximately 50%, QoL
was measured using the Sickness Impact Profile (SIP) andstract; J Am Soc Nephrol 7:1473, 1996. These results
suggest that normalization of Hct may have an added functional status was measured using the Karnofsky scale.
The results show that normalized Hct is associated withbeneficial effect on improving cognitive function and the
quality of sleep in dialysis patients. an improvement in physical and psychosocial scores as
well as in the mean global SIP score and functional status.
Physical function No adverse effects of epoetin therapy were observed [6].
Similar results were found in the Australian study [8].Anemia therapy with epoetin results in an increase in
working capacity and aerobic exercise [13, 28, 29] as the
Mortality and morbidityresult of an increased transport of oxygen to the muscular
tissue. Suzuki et al show that the VO2 is higher at a Hct Anemia has been shown to be a predictive risk factor
of mortality and morbidity [39–41]. In a Canadian studylevel of 35–40% than at 30% [30]. In a multi-center
study of 11 pre-dialysis patients, greater improvement of dialysis patients, each 1 g/dL decrease in Hb concen-
tration was independently associated with an improve-in energy and work capacity was observed when Hct was
increased from 28% to 38%. In these patients, oxygen ment in the relative risk of death of 1.14 [39]. Ma et al
studied the relationship between mortality and Hct in aconsumption at anaerobic threshold and at maximal ex-
ercise capacity increased, but did not reach normal val- group of 75,283 Medicare patients and found that the
relative risk of death decreased in patients with increasedues. This suggests that poor physical performance in
renal patients is not only due to anemia, but that other Hct. All causes of death (including cardiac causes) in
diabetic and non-diabetic patients were found to be atfactors such as neuropathy, cardiovascular disease, and
poor conditioning may also contribute [31]. the lowest incidence when Hct levels were in the range
33–36% [40]. In the study by Besarab of 1233 hemodialy-The effect of different Hb concentrations on maximal
exercise performance has also been studied in 14 hemo- sis patients with cardiac disease, patients in whom Hct
was increased to normal levels (42  3%) had higherdialysis patients. The results show that peak work rate
and peak VO2 significantly increase after normalization rates of mortality than the control group (Hct 30 
3%). However, this study included only patients withof Hb with no difference observed between young and
older patients [32]. congestive heart failure or ischemic heart diseases and
deaths were due to cardiovascular causes [9]. The study
Quality of life has been analyzed and criticized in two interesting edito-
rials [42, 43].In recent years, the evaluation of health-related QoL
has emerged as an important and useful tool for studying In a Medicare dialysis cohort of 71,717 patients, the
probability of hospitalization was found to be less whenthe efficacy and net benefit of medical therapies. In
ESRD patients, QoL has been shown to be worse than Hct levels were in the range 33–36% than when Hct
levels were lower [41]. Our co-operative Spanish groupthat of the general population and anemia has been im-
plicated as one of the main related factors [33]. has also studied the effect of Hct 36% on hospitaliza-
tion rates. It showed a significant decrease in the numberThe partial correction of anemia with epoetin is ac-
companied by an improvement in the QoL in both pre- of hospitalized patients and hospitalization length when
Hct was normalized [6]. More recently, Collins et al havedialysis [34] and dialysis [35–37] patients, and the as-
pects related to the physical dimension of the QoL score performed a retrospective study with incident hemodial-
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ysis patients with Medicare insurance. The authors show 51% [6], whereas in the Besarab study, the mean dose of
epoetin increased by approximately 200% [9].that for those patients with Hct 36%, hospitalization
rates were 16–22% lower than in the rest of the patients.
However, the relative risk of death was not different
OPTIMIZATION OF EPOETIN THERAPYbetween patients with Hct values of 36–39% compared
Currently, there is strong evidence that total correc-with those with values of 33–36% [44].
tion of anemia by normalizing Hb concentrations offersIn summary, partial correction of anemia in ESRD
clear benefits in selected patients with CKD. It no longerpatients has a beneficial effect on mortality and morbid-
seems reasonable to allow the development of anemiaity, but complete correction may provide further im-
and its deleterious effects on these patients. Thus, theprovements in some selected patients.
most appropriate target Hb concentration should be cor-
rection to normal levels. The main concerns over this
POTENTIAL ADVERSE EFFECTS OF A objective include the high costs and possible adverse
NORMAL TARGET Hb effects on selected groups of patients. Consequently, the
recommendation of normalizing Hb is not appropriateHigh Hb concentrations increases blood viscosity and
for all dialysis patients and the target Hb should bemay potentially play a role in the coagulation and throm-
tailored to the clinical conditions of each individual pa-bosis of vascular access for hemodialysis. Very few stud-
tient, bearing in mind his/her age, sex, physical activity,ies have evaluated the role that normalization of Hct
dialysis modality, and co-morbidity factors. As Macdou-may have on vascular access. During a mean follow-up
gall suggests, a normal Hb may be appropriate for youngperiod of 49 months, the US Normal Hct Trial showed
patients, in full-time employment, physically active, andthat high Hct levels are not associated with greater inci-
with no severe co-morbidity, whereas partial correctiondence of vascular access thrombosis [9]. Thrombosis of
of anemia would be reserved for elderly patients withvascular access was evaluated during the 6-month period
significant co-morbidities [49].of the Spanish co-operative study on the normalization of
Overall, we are seeing greater evidence as to the needthe Hct. This study found that 5.7% of patients suffered a
to begin treatment with epoetin in the early stages ofthrombosis of the vascular access. The cumulative vascu-
CKD, which has the potential to prevent anemia and itslar access survival at 6 months (CI 95%) was 0.93 0.04.
cardiovascular complications. To initiate therapy whenEven though the complications of the vascular accesses
Hb levels fall below 11 g/dL is probably too late. By then,are very different between centers, making comparisons
many patients will have severe, irreversible LVH as well asbetween them difficult, it does not seem that correct-
other complications due to the effect of prolonged anemia.ing anemia has a detrimental effect on vascular access
[45–47]. However, studies specially designed to research Reprint requests to Dr. Fernando Carrera, Department of Neph-
rology, Hospital SAMS, Rua Cidade de Gabela, 1, 1800-083 Lisbon,anemia and other potentially contributory factors to
Portugal.thrombosis are necessary. Currently, it seems reasonable E-mail: nefrologiasams@mail.telepac.pt
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